The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Nov 2016 07:30

RNS Number : 9985P
GW Pharmaceuticals PLC
24 November 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

GW Pharmaceuticals PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

x

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: iii

The Goldman Sachs Group, Inc.

4. Full name of shareholder(s) (if different from 3.):iv

Goldman Sachs International

Goldman, Sachs & Co.

Goldman Sachs Asset Management, L.P.

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

18 November 2016

6. Date on which issuer notified:

22 November 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

Below 3%

     
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

GB0030544687

94,532

94,532

 

 

Below 3%

 

Below 3%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

Below 3%

Below 3%

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

 

 

 

 

Below 3%

 

Below 3%

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

Below 3%

Below 3%

             

 

 

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

13. Additional information:

General email contact:

shareholderdisclosures@gs.com

 

14. Contact name:

Joanna Foley

15. Contact telephone number:

+44 207 051 9996

 

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAPFDAEAKFFF
Date   Source Headline
1st Dec 201611:15 amRNSAmerican Society of Epilepsy Annual Meeting
30th Nov 20161:00 pmRNSNotice of Q4 and year-end results
24th Nov 20167:30 amRNSHolding(s) in Company
22nd Nov 20161:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
18th Nov 20169:31 amRNSHolding(s) in Company
11th Nov 20165:01 pmRNSHolding(s) in Company
10th Nov 201611:03 amRNSDirector/PDMR Shareholding
3rd Nov 20161:58 pmRNSDirector/PDMR Shareholding
3rd Nov 20167:50 amRNSHolding(s) in Company
3rd Nov 20167:47 amRNSHolding(s) in Company
2nd Nov 20165:05 pmRNSDirector/PDMR Shareholding
1st Nov 20169:58 amRNSDirector/PDMR Shareholding
31st Oct 20163:29 pmRNSHolding(s) in Company
31st Oct 20162:59 pmRNSTotal Voting Rights
31st Oct 20168:25 amRNSHolding(s) in Company
28th Oct 20164:58 pmRNSDirector Stock Trading Plan
28th Oct 20164:57 pmRNSDirector/PDMR Shareholding
26th Oct 20165:26 pmRNSDirector/PDMR Shareholding
25th Oct 20165:43 pmRNSDirector/PDMR Shareholding
21st Oct 20164:37 pmRNSPosting of Shareholder Circular
20th Oct 20163:30 pmRNSHolding(s) in Company
19th Oct 20167:00 amRNSIntention to Trade Exclusively on NASDAQ
7th Oct 201610:22 amRNSDirector Stock Trading Plan - Replacement
6th Oct 20166:01 pmRNSDirector Stock Trading Plan
30th Sep 20161:48 pmRNSTotal Voting Rights
26th Sep 201611:57 amRNSSecond Positive Phase 3 Trial for Epidiolex in LGS
14th Sep 20165:27 pmRNSDirector/PDMR Shareholding
7th Sep 201612:00 pmRNSPresenting at Morgan Stanley Healthcare Conference
31st Aug 201612:18 pmRNSTotal Issued Share Capital
17th Aug 20168:56 amRNSBlock listing Interim Review
9th Aug 201612:00 pmRNS3rd Quarter Results
9th Aug 201612:00 pmRNSNotification of Future Change to Board
2nd Aug 201612:00 pmRNSNotice of Results
29th Jul 201610:58 amRNSTotal Voting Rights
25th Jul 20167:57 amRNSHolding(s) in Company
21st Jul 201610:08 amRNSHolding(s) in Company
21st Jul 201610:04 amRNSHolding(s) in Company
19th Jul 20169:37 amRNSTotal Voting Rights
18th Jul 20164:15 pmRNSClosing of U.S. Public Offering Raising $289.8m
13th Jul 20167:00 amRNSUS Public Offering of ADSs Raising $252.0 Million
13th Jul 20167:00 amRNSProposed Public Offering of ADSs
1st Jul 20163:14 pmRNSHolding(s) in Company
1st Jul 20168:03 amRNSHolding(s) in Company
30th Jun 20163:22 pmRNSTotal Voting Rights
28th Jun 201612:14 pmRNSHolding(s) in Company
27th Jun 201612:07 pmRNSSecond Price Monitoring Extn
27th Jun 201612:02 pmRNSPrice Monitoring Extension
27th Jun 201612:00 pmRNSPositive Phase 3 Pivotal Trial Results
27th Jun 201610:00 amRNSHolding(s) in Company
23rd Jun 20167:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.